NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines

(2009) T Zaremba et al.   BRITISH JOURNAL OF CANCER

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

(2009) R. A. Daniel et al.   CLINICAL CANCER RESEARCH

PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications

(2009) Yvette Drew et al.   DRUG RESISTANCE UPDATES

The IKK complex contributes to the induction of autophagy

(2009) Alfredo Criollo et al.   EMBO JOURNAL

Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia

(2009) Saman Hewamana et al.   JOURNAL OF CLINICAL ONCOLOGY

NF-κB and cancer: how intimate is this relationship

(2009) Sahdeo Prasad et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

A Nuclear Poly(ADP-Ribose)-Dependent Signalosome Confers DNA Damage-Induced IκB Kinase Activation

(2009) Michael Stilmann et al.   MOLECULAR CELL

The NF-κB-independent functions of IKK subunits in immunity and cancer

(2009) Alain Chariot   TRENDS IN CELL BIOLOGY

The NF- B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target

(2008) S. Hewamana et al.   BLOOD

The Novel Nuclear Factor- B Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine

(2008) S. Hewamana et al.   CLINICAL CANCER RESEARCH

Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Ionizing radiation-induced NF-κB activation requires PARP-1 function to confer radioresistance

(2008) S J Veuger et al.   ONCOGENE